Effects of the Off-Label Drug Prescription in the Paediatric Population in Spain from the Adoption of the Latest European Regulation: A Pre-Post Study.

off-label prescription paediatric regulation paediatrics pharmaceutical products prescription drugs primary health care

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
20 Apr 2021
Historique:
received: 26 02 2021
revised: 09 04 2021
accepted: 17 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

The year 2021 marks the 15th anniversary of the Paediatric Regulation (1901/2006/EC) in Europe. The main aim of the study was to conduct a pre-post comparison on the annual off-label prescription rates in the under-18 population in Spain and assess the potential influence of the Paediatric Regulation adoption. An observational study in the paediatric population was performed. Four cross-sectional annual periods, one before and the three latest periods after the adoption of the Regulation, were compared. Prescriptions in the primary health care setting were sorted by age group and drug and off-label status were determined. The number of off-label prescriptions issued by paediatricians was over two million per year. Prior to the adoption of the Paediatric Regulation, the off-label prescription rate was estimated at 7% of total prescriptions. Although the increase in the off-label rate over the study periods was mild, it was statistically significant (OR: 1.045; 95% CI: 1.043-1.046;

Identifiants

pubmed: 33924282
pii: pharmaceutics13040588
doi: 10.3390/pharmaceutics13040588
pmc: PMC8074896
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Pediatr. 2020 May;179(5):839-847
pubmed: 31897842
An Pediatr (Barc). 2017 Jan;86(1):28-36
pubmed: 27151379
Pharmaceutics. 2020 Jul 20;12(7):
pubmed: 32698409
Eur J Clin Pharmacol. 2010 Jun;66(6):633-41
pubmed: 20204337
Med Intensiva. 2016 Jan-Feb;40(1):1-8
pubmed: 25583042
J Evid Based Med. 2020 Nov;13(4):292-300
pubmed: 33047516
An Pediatr (Barc). 2014 Jul;81(1):16-21
pubmed: 24286874
J Okla State Med Assoc. 2018 Oct;111(8):776-783
pubmed: 31379392

Auteurs

Irene Lizano-Díez (I)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Itziar Aldalur-Uranga (I)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Carlos Figueiredo-Escribá (C)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Cecilia F Lastra (CF)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Eduardo L Mariño (EL)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Pilar Modamio (P)

Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII 27-31, 08028 Barcelona, Spain.

Classifications MeSH